Full Text View
Tabular View
No Study Results Posted
Related Studies
Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults
This study has been completed.
Study NCT00048360   Information provided by GlaxoSmithKline
First Received: October 30, 2002   Last Updated: February 24, 2006   History of Changes

October 30, 2002
February 24, 2006
October 2002
 
ADHD Rating Scale
Same as current
Complete list of historical versions of study NCT00048360 on ClinicalTrials.gov Archive Site
  • Clinical Global Impressions -Severity and Improvement.
  • Quality of Life Enjoyment and Satisfaction Questionnaire.
Same as current
 
Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults
An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Comparison of Extended-Release Bupropion Hydrochloride 300-450 Mg/Day to Assess the Efficacy, Safety, and Effects on Health Outcomes in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

This is a placebo controlled study evaluating the efficacy and safety of medication in adults with Attention-Deficit Hyperactivity Disorder (ADHD).

 
Phase III
Interventional
Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Attention Deficit Disorder
Drug: Extended-release bupropion hydrochloride
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
162
 
 

Inclusion criteria:

  • Patient must be diagnosed with ADHD.

Exclusion Criteria:

  • Patient has a current or past history of seizure disorder, brain injury, anorexia nervosa or bulimia.
  • Patient has a current diagnosis of Major Depressive Disorder (MDD).
  • Patient has a current primary diagnosis of, or received treatment for, Panic Disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD) or Acute Stress Disorder within the previous 12 months.
  • Patient has a lifetime diagnosis of bipolar disorder, schizophrenia or other psychotic disorders.
  • Patient has a positive urine test at screening for presence of illicit drugs or alcohol abuse during the past 12 months.
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00048360
 
AK130934
GlaxoSmithKline
 
Study Chair: GSK Clinical Trial, MD GlaxoSmithKline
GlaxoSmithKline
February 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP